| NCT03807440DIA_CENTRAL:T2D Treatment Pattern in Central Europe | GLP-1 / incretin class catch-all Type 2 diabetes | - | - | Completed | 177 | Aug 2021 | 1 | results |
| BRIGHTEfficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist | GLP-1 / incretin class catch-all Type 2 diabetes | - | Ph 4 | Completed | 158 | Aug 2017 | 1 | results |
| SURPASS-2A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | GLP-1 / incretin class catch-all, Semaglutide, Tirzepatide Type 2 diabetes | BMI ≥25 | Ph 3 | Completed | 127 | Jan 2021 | 9 | results |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | - | Ph 3 | Completed | 124 | May 2018 | 5 | results |
| DUAL™ IIIThe Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy | Exenatide, GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 109 | Mar 2014 | 3 | results |
| NCT00635492CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy | Exenatide, GLP-1 / incretin class catch-all Type 2 diabetes | - | - | Completed | 96 | Dec 2011 | 2 | results |
| NCT05579977Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity | GLP-1 / incretin class catch-all, Lotiglipron, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 2 | Terminated | 90 | Jul 2023 | 2 | results |
| STARS extendOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | GLP-1 / incretin class catch-all Gastrointestinal (gastroparesis / short bowel / pancreatitis) | - | Ph 3 | Active, not recruiting | 66 | Oct 2027 | - | |
| PRECIDENTDPREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Dulaglutide, GLP-1 / incretin class catch-all, Liraglutide, Semaglutide Cardiovascular disease, Type 2 diabetes | Established ASCVD/CKD | Ph 4 | Recruiting | 36 | Mar 2029 | 1 | |
| GRADEA Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | HbA1c 6.8-8.5% | Ph 3 | Completed | 36 | Apr 2021 | 61 | results |
| NCT04952779Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | GLP-1 / incretin class catch-all, Liraglutide Type 2 diabetes | - | - | Completed | 32 | Dec 2024 | - | |
| FLAMESFibrosis Lessens After Metabolic Surgery | GLP-1 / incretin class catch-all, Liraglutide, Semaglutide, Tirzepatide Bariatric Surgery Candidate, MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 35-70 | Ph 4 | Recruiting | 22 | May 2029 | - | |
| NCT06833749Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | GLP-1 / incretin class catch-all, KBP-336 Obesity / overweight, Osteoarthritis, Pain | BMI ≥30 | Ph 2 | Recruiting | 20 | Nov 2026 | - | |
| GETGOAL-XGLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Exenatide, GLP-1 / incretin class catch-all, Lixisenatide Type 2 diabetes | - | Ph 3 | Completed | 18 | Nov 2010 | 2 | results |
| NCT06732245Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | GLP-1 / incretin class catch-all, NA-931, Tirzepatide Obesity / overweight | BMI ≥30 | Ph 2 | Not yet recruiting | 17 | Aug 2027 | - | |
| NCT02589626Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA | GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≤40 | Ph 4 | Completed | 16 | Jun 2017 | 1 | results |
| SERENASemaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes | GLP-1 / incretin class catch-all, Semaglutide Gestational diabetes, Prediabetes / glucose intolerance | Female | Ph 3 | Recruiting | 13 | Jun 2029 | - | |
| NCT01303315TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy | GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≤40 | Not applicable | Terminated | 13 | Jul 2011 | - | |
| NCT05415410Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) | GLP-1 / incretin class catch-all | - | Ph 2 | Terminated | 13 | Dec 2024 | - | results |
| SEVERALSEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | - | Completed | 11 | Nov 2023 | 14 | |
| NCT02537834Tofogliflozin GLP-1 Analogue Combination Trial | GLP-1 / incretin class catch-all Obesity / overweight, Type 2 diabetes | HbA1c 7.5-10.5% | Ph 4 | Completed | 11 | Jul 2017 | 1 | |
| NCT06003985Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists | GLP-1 / incretin class catch-all Perioperative / gastric aspiration risk | - | - | Completed | 8 | Jan 2025 | 3 | |
| PROACTA Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) | GLP-1 / incretin class catch-all, Semaglutide Obesity / overweight, Sarcopenia / muscle | BMI ≥30 | Ph 2 | Recruiting | 7 | Mar 2027 | - | |
| NCT02291874Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM) | GLP-1 / incretin class catch-all Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 6 | Jul 2016 | 1 | |
| MICRONThe MICRON Study - A Steno 1 Substudy | GLP-1 / incretin class catch-all Type 1 diabetes | BMI ≥35 | - | Recruiting | 5 | Jul 2028 | 1 | |
